
We’re excited to share more about Indonesia’s NHI system! It’s incredible to see how they implemented universal healthcare and overcame unique challenges.
These insights are based on a recent interview by Alec Hogg and Ali Ghufron Mukti but through the lens of health economics and outcomes research, and access to medicines.
Of course, no system is perfect, and Indonesia’s NHI journey reminds us of the importance of constant vigilance to address challenges like funding and corruption issues.
Thank you for sharing these important lessons!
Recent Posts

FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease
The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.

Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration
A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.

Cemiplimab Cervical Cancer Access Navigating Treatment and Value
Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...